PET/NIR-II fluorescence imaging and image-guided surgery of glioblastoma using a folate receptor α-targeted dual-modal nanoprobe
- PMID: 35838757
- DOI: 10.1007/s00259-022-05890-x
PET/NIR-II fluorescence imaging and image-guided surgery of glioblastoma using a folate receptor α-targeted dual-modal nanoprobe
Abstract
Purpose: The surgery of glioblastoma (GBM) requires a maximal resection of the tumor when it is safe and feasible. The infiltrating growth property of the GBM makes it a challenge for neurosurgeons to identify the tumor tissue even with the assistance of the surgical microscope. This highlights the urgent requirement for imaging techniques that can differentiate tumor tissues during surgery in real time. Fluorescence image-guided surgery of GBM has been investigated using several non-specific fluorescent probes that emit light in the visible and the first near-infrared window (NIR-I, 700-900 nm), which limit the detection accuracy because of the non-specific targeting mechanism and spectral characteristics. Targeted NIR-II (1000-1700 nm) fluorescent probes for GBM are thus highly desired. The folate receptor (FR) has been reported to be upregulated in GBM, which renders it to be a promising target for specific tumor imaging.
Methods: In this study, the folic acid (FA) that can target the FR was conjugated with the clinically approved indocyanine green (ICG) dye and DOTA chelator for radiolabeling with 64Cu to achieve targeted positron emission tomography (PET) and fluorescence imaging of GBM.
Results: Surprisingly it was found that the resulted bioconjugate, DOTA-FA-ICG and non-radioactive natCu-DOTA-FA-ICG, were both self-assembled into nanoparticles with NIR-II emission signal. The radiolabeled DOTA-FA-ICG, 64Cu-DOTA-FA-ICG, was found to specifically accumulate in the orthotopic GBM models using in vivo PET, NIR-II, and NIR-I fluorescence imaging. The best time window of fluorescence imaging was demonstrated to be 24 h after DOTA-FA-ICG injection. NIR-II fluorescence image-guided surgery was successfully conducted in the orthotopic GBM models using DOTA-FA-ICG. All the fluorescent tissue was removed and proved to be GBM by the H&E examination.
Conclusion: Overall, our study demonstrates that the probes, 64Cu-DOTA-FA-ICG and DOTA-FA-ICG, hold promise for preoperative PET examination and intraoperative NIR-II fluorescence image-guided surgery of GBM, respectively.
Keywords: Fluorescence image-guided surgery; Folate receptor α; Glioblastoma; NIR-II imaging probe.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Molecular Targeted NIR-II Probe for Image-Guided Brain Tumor Surgery.Bioconjug Chem. 2018 Nov 21;29(11):3833-3840. doi: 10.1021/acs.bioconjchem.8b00669. Epub 2018 Oct 23. Bioconjug Chem. 2018. PMID: 30296054 Free PMC article.
-
Preoperative PET imaging and fluorescence-guided surgery of human glioblastoma using dual-labeled antibody targeting ETA receptors in a preclinical mouse model: A theranostic approach.Theranostics. 2024 Sep 30;14(16):6268-6280. doi: 10.7150/thno.98163. eCollection 2024. Theranostics. 2024. PMID: 39431005 Free PMC article.
-
First-in-human study of PET and optical dual-modality image-guided surgery in glioblastoma using 68Ga-IRDye800CW-BBN.Theranostics. 2018 Apr 3;8(9):2508-2520. doi: 10.7150/thno.25599. eCollection 2018. Theranostics. 2018. PMID: 29721096 Free PMC article. Clinical Trial.
-
Folic acid-indocyanine green-poly(d,l-lactide-coglycolide)-lipid nanoparticles.2012 Aug 30 [updated 2012 Sep 27]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2012 Aug 30 [updated 2012 Sep 27]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 23035307 Free Books & Documents. Review.
-
Bovine serum albumin–stabilized gold nanoclusters conjugated with folate and indocyanine green derivative 02.2012 Oct 4 [updated 2013 Jan 24]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2012 Oct 4 [updated 2013 Jan 24]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 23367530 Free Books & Documents. Review.
Cited by
-
The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts.Protein Cell. 2025 Jul 19;16(7):532-556. doi: 10.1093/procel/pwaf002. Protein Cell. 2025. PMID: 39813112 Free PMC article. Review.
-
Development of a fibroblast activation protein-targeted PET/NIR dual-modality probe and its application in head and neck cancer.Front Bioeng Biotechnol. 2023 Nov 3;11:1291824. doi: 10.3389/fbioe.2023.1291824. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 38026901 Free PMC article.
-
Nanoprobe-Based Near-Infrared II Optical Imaging for Guiding Precision Glioma Therapy.Int J Nanomedicine. 2025 Jun 27;20:8433-8449. doi: 10.2147/IJN.S523676. eCollection 2025. Int J Nanomedicine. 2025. PMID: 40599397 Free PMC article. Review.
-
Recent Advances in Indocyanine Green-Based Probes for Second Near-Infrared Fluorescence Imaging and Therapy.Research (Wash D C). 2025 Jan 17;8:0583. doi: 10.34133/research.0583. eCollection 2025. Research (Wash D C). 2025. PMID: 39830366 Free PMC article. Review.
-
Orbital Adipose Tissue: The Optimal Control for Back-Table Fluorescence Imaging of Orbital Tumors.Bioengineering (Basel). 2024 Sep 14;11(9):922. doi: 10.3390/bioengineering11090922. Bioengineering (Basel). 2024. PMID: 39329664 Free PMC article.
References
-
- Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro-Oncol. 2020;22(Supplement_1):iv1–96. https://doi.org/10.1093/neuonc/noaa269 . - PubMed - PMC
-
- Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA: A Cancer J Clin. 2020;70(4):299–312. https://doi.org/10.3322/caac.21613 .
-
- Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, et al. Association of the extent of resection with survival in glioblastoma: a systematic review and meta-analysis. JAMA Oncol. 2016;2(11):1460–9. https://doi.org/10.1001/jamaoncol.2016.1373 . - PubMed - PMC
-
- Molinaro AM, Hervey-Jumper S, Morshed RA, Young J, Han SJ, Chunduru P, et al. Association of maximal extent of resection of contrast-enhanced and non–contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma. JAMA Oncol. 2020;6(4):495–503. https://doi.org/10.1001/jamaoncol.2019.6143 . - PubMed - PMC
-
- Suchorska B, Jansen NL, Linn J, Kretzschmar H, Janssen H, Eigenbrod S, et al. Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology. 2015;84(7):710–9. https://doi.org/10.1212/WNL.0000000000001262 . - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous